A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination With High Dose Interferon-Alpha in Advanced Melanoma
PRIMARY OBJECTIVES:
I. Test the hypothesis that the combination of ipilimumab and high-dose interferon (HDI
[recombinant interferon alfa-2b]) will improve progression free survival (PFS) of patients
with advanced metastatic melanoma as compared to ipilimumab alone (across ipilimumab
treatment status).
SECONDARY OBJECTIVES:
I. Test the hypothesis that the combination of ipilimumab and HDI will prove to be safe and
tolerable.
II. Within the constraints of the sample size, attempt to test the hypotheses that (1)
ipilimumab 10 mg/kg will lead to improved PFS in comparison to ipilimumab 3 mg/kg (across
HDI treatment status); (2) the combination of ipilimumab and HDI will improve overall
survival (OS) of patients with advanced metastatic melanoma as compared to ipilimumab alone
(across ipilimumab treatment status) and (3) ipilimumab 10 mg/kg will lead to improved OS in
comparison to ipilimumab 3 mg/kg (across HDI treatment status).
OUTLINE: Patients are randomized to 1 of 4 treatment arms.
ARM A:
INDUCTION PHASE: Patients receive higher dose ipilimumab intravenously (IV) over 90 minutes
once every 3 weeks for 4 doses and recombinant interferon alfa-2b IV over 20 minutes five
days a week for 4 weeks and then subcutaneously (SC) three times weekly for 8 weeks.
MAINTENANCE PHASE: Patients receive higher dose ipilimumab IV over 90 minutes once every 12
weeks for 4 doses beginning in week 24 and recombinant interferon alfa-2b SC three times
weekly for 48 weeks.
ARM B:
INDUCTION PHASE: Patients receive higher dose ipilimumab IV over 90 minutes once every 3
weeks for 4 doses.
MAINTENANCE PHASE: Patients receive higher dose ipilimumab IV over 90 minutes once every 12
weeks for 4 doses beginning in week 24.
ARM C:
INDUCTION PHASE: Patients receive lower dose ipilimumab IV over 90 minutes once every 3
weeks for 4 doses and recombinant interferon alfa-2b IV over 20 minutes five days a week for
4 weeks and then SC three times weekly for 8 weeks.
MAINTENANCE PHASE: Patients receive lower dose ipilimumab IV over 90 minutes once every 12
weeks for 4 doses beginning in week 24 and recombinant interferon alfa-2b SC three times
weekly for 48 weeks.
ARM D:
INDUCTION PHASE: Patients receive lower dose ipilimumab IV over 90 minutes once every 3
weeks for 4 doses.
MAINTENANCE PHASE: Patients receive lower dose ipilimumab IV over 90 minutes once every 12
weeks for 4 doses beginning in week 24.
In all arms, treatment continues in the absence of disease progression or unacceptable
toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years,
every 6 months for 3 years, and then annually for up to 5 years.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression-free survival (PFS)
The distribution of PFS will be compared using the log-rank test.
Up to 10 years
No
Ahmad Tarhini
Principal Investigator
Eastern Cooperative Oncology Group
United States: Food and Drug Administration
NCI-2012-01932
NCT01708941
January 2013
Name | Location |
---|---|
Boulder Community Hospital | Boulder, Colorado 80301-9019 |
Porter Adventist Hospital | Denver, Colorado 80210 |
Rose Medical Center | Denver, Colorado 80220 |
Swedish Medical Center | Englewood, Colorado 80110 |
Sky Ridge Medical Center | Lone Tree, Colorado 80124 |
Via Christi Regional Medical Center | Wichita, Kansas 67214 |
North Colorado Medical Center | Greeley, Colorado 80631 |
McKee Medical Center | Loveland, Colorado 80539 |
Cancer Center of Kansas - Chanute | Chanute, Kansas 66720 |
Cancer Center of Kansas - Dodge City | Dodge City, Kansas 67801 |
Cancer Center of Kansas - Newton | Newton, Kansas 67114 |
Cancer Center of Kansas - Salina | Salina, Kansas 67042 |
Cancer Center of Kansas - Wellington | Wellington, Kansas 67152 |
Associates in Womens Health | Wichita, Kansas 67203 |
Cancer Center of Kansas - Winfield | Winfield, Kansas 67156 |
Adena Regional Medical Center | Chillicothe, Ohio 54601 |
Grady Memorial Hospital | Delaware, Ohio 43015 |
Fairfield Medical Center | Lancaster, Ohio 43130 |
Community Cancer Center of Monroe | Monroe, Michigan 48162 |
Lima Memorial Hospital | Lima, Ohio 45804 |
Fulton County Health Center | Wauseon, Ohio 43567 |
Exempla Lutheran Medical Center | Wheat Ridge, Colorado 80033 |
Bixby Medical Center | Adrian, Michigan 49221 |
Swedish American Hospital | Rockford, Illinois 61104 |
Cancer Center of Kansas - Fort Scott | Fort Scott, Kansas 66701 |
Cancer Center of Kansas-Independence | Independence, Kansas 67301 |
Lawrence Memorial Hospital | Lawrence, Kansas 66044 |
Longmont United Hospital | Longmont, Colorado 80501 |
University of Pittsburgh | Pittsburgh, Pennsylvania 15261 |
Riverside Methodist Hospital | Columbus, Ohio 43214 |
Licking Memorial Hospital | Newark, Ohio 43055-2899 |
Cancer Center of Kansas - McPherson | McPherson, Kansas 67460 |
Columbus CCOP | Columbus, Ohio 43206 |
Presbyterian - Saint Lukes Medical Center - Health One | Denver, Colorado 80218 |
Wichita CCOP | Wichita, Kansas 67214-3882 |
Flower Hospital | Sylvania, Ohio 43560-2197 |
Decatur Memorial Hospital | Decatur, Illinois 62526 |
Littleton Adventist Hospital | Littleton, Colorado 80122 |
Parker Adventist Hospital | Parker, Colorado 80138 |
The Medical Center of Aurora | Aurora, Colorado 80012 |
Penrose-Saint Francis Healthcare | Colorado Springs, Colorado 80907 |
Saint Anthony Central Hospital | Denver, Colorado 80204 |
Exempla Saint Joseph Hospital | Denver, Colorado 80218 |
Colorado Cancer Research Program CCOP | Denver, Colorado 80224-2522 |
Saint Mary Corwin Medical Center | Pueblo, Colorado 81004 |
Mercy Medical Center-Sioux City | Sioux City, Iowa 51104 |
Saint Luke's Regional Medical Center | Sioux City, Iowa 51104 |
Cancer Center of Kansas - El Dorado | El Dorado, Kansas 67042 |
Cancer Center of Kansas-Kingman | Kingman, Kansas 67068 |
Cancer Center of Kansas - Parsons | Parsons, Kansas 67357 |
Cancer Center of Kansas - Pratt | Pratt, Kansas 67124 |
Cancer Center of Kansas-Wichita Medical Arts Tower | Wichita, Kansas 67208 |
Cancer Center of Kansas - Main Office | Wichita, Kansas 67214 |
Hickman Cancer Center | Adrian, Michigan 49221 |
Mercy Memorial Hospital | Monroe, Michigan 48162 |
Doctors Hospital | Columbus, Ohio 43228 |
Grant Medical Center | Columbus, Ohio 43215 |
Mount Carmel Health Center West | Columbus, Ohio 43222 |
Marietta Memorial Hospital | Marietta, Ohio 45750 |
Saint Charles Hospital | Oregon, Ohio 43616 |
Toledo Community Hospital Oncology Program CCOP | Toledo, Ohio 43617 |
University of Toledo | Toledo, Ohio 43614 |
Saint Vincent Mercy Medical Center | Toledo, Ohio 43608 |
Genesis HealthCare System | Zanesville, Ohio 43701 |
Saint Vincent Hospital | Green Bay, Wisconsin 54301 |
Cancer Center of Kansas-Liberal | Liberal, Kansas 67901 |
Holy Family Memorial Hospital | Manitowoc, Wisconsin 54221 |
Southern Ohio Medical Center | Portsmouth, Ohio 45662 |
Saint Nicholas Hospital | Madison, Wisconsin 53715 |
New York Oncology Hematology PC -Albany Medical Center | Albany, New York 12208 |
Siouxland Hematology Oncology Associates | Sioux City, Iowa 51101 |
The Toledo Hospital/Toledo Children's Hospital | Toledo, Ohio 43606 |
Toledo Clinic Cancer Centers-Oregon | Oregon, Ohio 43616 |
Springfield Regional Medical Center | Springfield, Ohio 45505 |
Toledo Clinic Cancer Centers-Maumee | Maumee, Ohio 43537-1839 |
Toledo Clinic Cancer Centers-Toledo | Toledo, Ohio 43623 |